All In Biotech

Drug Trial Radar · NCT02914522

Study to Evaluate the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Ulcerative Colitis

Combined Phase 2b/3, Double-Blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects With Moderately to Severely Active Ulcerative Colitis

Last checked: Nov 19, 2026Latest source record: Apr 21, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,351 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,351

Actual

Start

Nov 14, 2016

Primary completion

Mar 31, 2020

Study completion Mar 31, 2020

Sponsor

Lead sponsor
Gilead SciencesGilead Sciences (GILD)
Sponsor type
Industry
Collaborators
Lakefront Biotherapeutics NV
First posted
Sep 26, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objectives of this study are to evaluate the efficacy of filgotinib in the induction and maintenance treatment of moderately to severely active ulcerative colitis (UC) in participants who are biologic-naive and biologic-experienced. Participants who complete the study, or met protocol specified efficacy discontinuation criteria will have the option to enter a separate, long-term extension (LTE) study (Gilead Study GS-US-418-3899: NCT02914535).

Conditions

  • Ulcerative Colitis

Interventions

  • FilgotinibDrug

    Tablet(s) administered orally once daily

  • PTM filgotinibDrug

    Tablet(s) administered orally once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Induction Study: Percentage of Participants Who Achieved Endoscopy/Bleeding/Stool Frequency (EBS) Remission at Week 10Time frame: Week 10
  2. Maintenance Study: Percentage of Participants Who Achieved EBS Remission at Week 58Time frame: Week 58

Locations

343 sites in 40 countries. Site status is shown where the registry gives one.

  • Digestive Health Specialists of the Southeast

    Dothan, Alabama

  • Mayo Clinic Arizona

    Scottsdale, Arizona

  • VA Long Beach Healthcare System

    Long Beach, California

  • Cedars Sinai Medical Center

    Los Angeles, California

  • South Denver Gastroenterology, PC

    Lone Tree, Colorado

  • Connecticut GI PC-Research Division

    Farmington, Connecticut

  • UF Health at Shands Hospital

    Gainesville, Florida

  • Florida Research Institute

    Lakewood Rch, Florida

  • University of Miami Crohn's and Colitis Center

    Miami, Florida

  • Cordova Research Institute

    Miami, Florida

  • Gastroenterology Group of Naples

    Naples, Florida

  • Advanced Medical Research Center

    Port Orange, Florida

  • Tampa General Hospital

    Tampa, Florida

  • Shafran Gastroenterology Center

    Winter Park, Florida

  • Florida Medical Clinic, P.A.

    Zephyrhills, Florida

  • Gastroenterology Associates of Central Georgia, LLC

    Macon, Georgia

  • Gastrointestinal Specialists of Georgia

    Marietta, Georgia

  • Atlanta Gastroenterology Specialist, PC

    Suwanee, Georgia

  • University of Iowa Hospitals and Clinics

    Iowa City, Iowa

  • University of Louisville, Clinical Trials Unit

    Louisville, Kentucky

  • Delta Research Partners, LLC

    Monroe, Louisiana

  • Louisiana Research Center, LLC

    Shreveport, Louisiana

  • Investigative Clinical Research

    Annapolis, Maryland

  • MGG Group Co., Inc., Chevy Chase Clinical Research

    Chevy Chase, Maryland

  • Gastro Center of Maryland

    Columbia, Maryland

  • Meritus Center for Clinical Research

    Hagerstown, Maryland

  • Massachusetts General Hospital - Crohn's and Colitis Center

    Boston, Massachusetts

  • Clinical Research Institute of Michigan, LLC

    Chesterfield, Michigan

  • Center for Digestive Health

    Troy, Michigan

  • Mayo Clinic

    Rochester, Minnesota

  • Kansas City Research Institute

    Kansas City, Missouri

  • Washington University School of Medicine

    St Louis, Missouri

  • NY Scientific

    Brooklyn, New York

  • NYU Langone Long Island Clinical Research Associates

    Great Neck, New York

  • Carolina's GI Research, LLC

    Raleigh, North Carolina

  • Fargo Gastroenterology and Hepatology Clinic

    Fargo, North Dakota

  • Consultants for Clinical Research

    Cincinnati, Ohio

  • UC Health Physicians Clifton

    Cincinnati, Ohio

  • Great Lakes Gastroenterology Research, LLC

    Mentor, Ohio

  • Gastroenterology Associates of Orangeburg

    Orangeburg, South Carolina

Showing 40 of 343 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.